Cyteir Therapeutics (Cyteir Therapeutics) Debt-to-EBITDA : -0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyteir Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.02 Mil. Cyteir Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Cyteir Therapeutics's annualized EBITDA for the quarter that ended in Sep. 2023 was $-20.24 Mil. Cyteir Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cyteir Therapeutics's Debt-to-EBITDA or its related term are showing as below:

CYTT's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.3
* Ranked among companies with meaningful Debt-to-EBITDA only.

Cyteir Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Cyteir Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Debt-to-EBITDA Chart

Cyteir Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

-0.02

Cyteir Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial											-0.02	-0.02	-	-	-

Competitive Comparison of Cyteir Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Cyteir Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyteir Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's Debt-to-EBITDA falls into.

Cyteir Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyteir Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.889	+	0)	/	-47.502
	=	-0.02

Cyteir Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.016	+	0)	/	-20.244
	=	-0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

Cyteir Therapeutics (OTCPK:CYTT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cyteir Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421

Website

https://www.cyteir.com

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness	officer: General Counsel	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey	director	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong	director	69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven	10 percent owner	BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421